# Castle Biosciences

Source: https://onco.cc/companies/castle-biosciences/  
OnCo record `castle-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An American laboratory company that sells gene-activity tests estimating how likely skin and eye cancers are to spread.

## Summary

Castle Biosciences makes tissue tests that measure the activity of a fixed set of genes by reverse-transcription PCR and report a risk class: DecisionDx-Melanoma (31 genes) for stage I to III skin melanoma, DecisionDx-UM (15 transcripts) for uveal melanoma, and DecisionDx-SCC (40 genes) for cutaneous squamous cell carcinoma. Medicare's MolDX programme covers the melanoma and uveal melanoma classes of test under local coverage determinations L37725 and L37033, and lists molecular risk tests for cutaneous squamous cell carcinoma as not covered (L39583).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- HQ: Friendswood, TX
- Type: diagnostics
- Website: https://www.castlebiosciences.com
- Ticker: CSTL

## Sources

- Castle Biosciences: https://www.castlebiosciences.com
- SEC EDGAR: Castle Biosciences filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001447362

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [DecisionDx-Melanoma](https://onco.cc/drugs/decisiondx-melanoma/), [DecisionDx-SCC](https://onco.cc/drugs/decisiondx-scc/), [DecisionDx-UM](https://onco.cc/drugs/decisiondx-um/)

---
JSON: https://onco.cc/api/v1/entities/castle-biosciences.json